← Human Trials & Peer-Reviewed Studies
Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes
Plain-language guide to PMID 16054266 (2006): open-label randomized controlled trial study of Insulin (regular human) and Insulin Aspart in 753 people.
Key Facts
- PMID
- 16054266
- Journal
- Diabetes research and clinical practice
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Home PD et al. (7 authors)
- DOI
- 10.1016/j.diabres.2005.05.015
- Registered trial
- NCT01707134
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin (regular human) and Insulin Aspart, published as a randomized controlled trial.
This was a 30-month extension of a multinational, multicentre, open-label, parallel-group study of 753 people with type 1 diabetes, originally randomly allocated to treatment with insulin aspart or unmodified human insulin before meals, with NPH insulin as basal insulin.
Main outcomes measures were hypoglycaemia (major or minor), adverse events and HbA(1c).
Who Took Part
The study group was 753 people.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, open-label, multicenter and parallel-group study.
The people were allocated by chance, so the Insulin (regular human) group and the comparison group should start out alike.
Everyone knew when Insulin (regular human) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
Running at several centres spread the Insulin (regular human) study over different clinics and patient groups.
The Insulin (regular human) group and the comparison group ran side by side rather than switching.
What Was Measured
Main outcomes measures were hypoglycaemia (major or minor), adverse events and HbA(1c).
Topics PubMed links to this paper include Body Mass Index, Eating, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Aspart and Insulin, Isophane.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Insulin (regular human) and Insulin Aspart in 753 people.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2006 (Diabetes research and clinical practice), a journal based in Ireland.
More context: the Insulin (regular human) compound page and the Insulin Aspart compound page.
Our Notes on the Compounds
Insulin (regular human): The 51-amino-acid pancreatic hormone that lowers blood glucose; this page covers regular (short-acting) insulin studied in human trials.
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
- Insulin (regular human) in the library
- Insulin Aspart in the library
- NPH Insulin (isophane) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.